Ocular Therapeutix, Inc. filings document the formal disclosure record for a Nasdaq-listed biopharmaceutical issuer developing and commercializing ophthalmic therapies. Form 8-K reports furnish operating and financial results, Regulation FD materials and clinical-trial disclosures tied to AXPAXLI in wet age-related macular degeneration, along with material-event reporting on governance matters, executive officer arrangements, material agreements and capital-structure disclosures.
Proxy materials cover shareholder voting matters, executive compensation and equity-award disclosures, including information presented under pay-versus-performance reporting. The filings also identify Ocular Therapeutix common stock, par value $0.0001 per share, as registered on The Nasdaq Global Market under the symbol OCUL.
Ocular Therapeutix, Inc. (OCUL) said Chief Strategy Officer Sanjay Nayak, M.B.B.S., Ph.D., resigned effective October 16, 2026. He notified the company on October 14, 2026, and is leaving to become chief executive officer of a privately held company.
Ocular Therapeutix (OCUL) Chief Legal Officer Todd Anderman sold 11,984 shares of common stock on October 8, 2026, at a weighted average price of $7.29 per share. The shares were sold in multiple transactions at prices ranging from $7.10 to $7.45, inclusive. The sale followed a durable automatic sale instruction adopted on October 7, 2024, to satisfy tax withholding obligations connected with restricted stock units that vested on October 7, 2026; it was not a discretionary trade. Direct holdings following the sale were 140,484 shares.
Ocular Therapeutix, Inc. (OCUL) officer Todd Anderman reported a proposed sale of 11,984 common shares, with an approximate sale date of October 8, 2026. The shares were acquired October 7, 2026 through restricted stock vesting under a registered plan. The listed aggregate market value is $87,315.42, and Morgan Stanley Smith Barney LLC is identified as the broker.
Ocular Therapeutix, Inc. (OCUL) Chief Development Officer Peter Kaiser sold 9,990 shares of common stock on October 2, 2026, at a weighted average price of $7.0500 per share.
The sale was made under a durable automatic sale instruction adopted April 9, 2024, to satisfy tax withholding obligations connected with restricted stock units that vested October 1, 2026. The sales were not discretionary. Peter Kaiser directly held 254,388 shares after the transaction.
Ocular Therapeutix, Inc. (OCUL) Chief Scientific Officer Jeffrey S. Heier sold 10,869 shares of common stock on October 2, 2026, at a weighted average price of $7.0500 per share. He directly held 307,457 shares after the sale. The sale was pursuant to a durable automatic sale instruction adopted by Heier on April 9, 2024, and was not discretionary. It covered tax withholding obligations connected with restricted stock units that vested on October 1, 2026.
Ocular Therapeutix, Inc. (OCUL) common shares are the subject of Officer Peter Kazuo Kaiser’s notice of a proposed sale of 9,990 shares, with an aggregate market value of $70,459.47 and an approximate sale date of October 2, 2026. The shares are listed as coming from restricted stock vesting under a registered plan on October 1, 2026. The notice also reports that Kaiser sold 3,035 common shares on August 24, 2026, for an aggregate market value of $32,701.82.
Ocular Therapeutix, Inc. officer Jeffrey S. Heier reported a proposed sale of 10,869 common shares with an aggregate market value of $76,639.49 and an approximate sale date of October 2, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services on Nasdaq. The shares are listed as restricted stock vesting under a registered plan on October 1, 2026. The notice also reports that Heier sold 3,296 common shares for $35,532.20 on August 24, 2026.
OCULAR THERAPEUTIX, INC (OCUL) reported that its Chief Operating Officer, Donald Notman, sold 1,099 shares of common stock on August 31, 2026, at a weighted average price of $10.24 per share in an open-market transaction. The sale was executed under a durable automatic sale instruction to satisfy tax withholding from restricted stock units vesting on August 29, 2026, and is described as non-discretionary. Following this transaction, Notman held 366,529 shares directly, which include 1,272 shares acquired under the company’s Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026.
OCULAR THERAPEUTIX, INC (OCUL) has a notice of proposed sale of common stock filed under Rule 144 on behalf of Donald D. Notman Jr. The filing covers 1,099 shares of common stock, described as restricted stock vesting under a registered plan, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services. The reported transaction date is August 31, 2026, with an indicated total value of $11,251.89.
OCULAR THERAPEUTIX, INC (OCUL) officer Peter Kaiser, Chief Development Officer, reported a sale of 3,035 shares of common stock on August 24, 2026, at a weighted average price of $10.77 per share. The transaction was executed under a pre-arranged durable automatic sale instruction to cover tax withholding on restricted stock units vesting on August 22, 2026, and is described as non-discretionary. After this sale, Kaiser directly holds 264,378 shares, which include 1,272 shares acquired under the company’s Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026.